Mersana Therapeutics, Inc. (MRSN)
Fuera de horario:
Mersana Therapeutics, Inc.
840 Memorial Drive
Cambridge, MA 02139
United States
617 498 0020
https://www.mersana.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 123
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Martin H. Huber M.D. | President, CEO & Director | 780.46k | N/D | 1961 |
| Mr. Brian C. DeSchuytner | Senior VP, CFO & COO | 567.04k | N/D | 1978 |
| Dr. Timothy B. Lowinger Ph.D. | Senior VP and Chief Science & Technology Officer | 587.53k | N/D | 1964 |
| Ms. Alejandra Veronica Carvajal J.D. | Senior VP, Secretary & Chief Legal Officer | 558.12k | N/D | 1974 |
| Mr. Mohan Bala Ph.D. | Senior VP & Chief Development Officer | 549.43k | N/D | 1965 |
| Mr. Mikhail Papisov Ph.D. | Co-Founder | N/D | N/D | N/D |
| Mr. Ashish Mandelia | Chief Accounting Officer | N/D | N/D | 1975 |
| Mr. Jason Fredette | Senior Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Mr. Chuck Miller | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
| Mr. Marc Damelin | Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop. | N/D | N/D | N/D |
Descripción
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Mersana Therapeutics, Inc. a partir del 1 de mayo de 2024 es 7. Las puntuaciones principales son Auditoría: 3; Junta: 6; Derechos del accionista: 8; Compensación: 9.
